NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE, Survivin, MUC1, Melan-A

Class

Plasmacytoid dendritic cell (PDC*line) platform multi-peptide therapeutic cancer vaccine (PDC*line Pharma SAS)

Pathway

Multi-antigen T-cell priming via irradiated allogeneic PDC line individually loaded with synthetic peptides

Notes

original target text: NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE, Survivin, MUC1, Melan-A (7 lung tumor-associated antigens)

This mechanism is a therapeutic cancer vaccine built to train the immune system to recognize lung tumor cells by exposing it to seven tumor-associated antigens: NY-ESO-1, MAGE-A3, MAGE-A4, additional MAGE family members, Survivin, MUC1, and Melan-A. These are proteins that are absent or scarce on normal adult tissue but re-expressed, often abundantly, on tumor cells, making them attractive flags for immune recognition. The platform uses an irradiated, non-dividing allogeneic plasmacytoid dendritic cell line — a manufactured, standardized antigen-presenting cell — individually loaded with synthetic peptide fragments of each target antigen. When injected, these cells present the peptides to the patient's own T cells, priming cytotoxic T lymphocytes capable of recognizing and killing tumor cells that display the same antigens on their surface. Using several antigens simultaneously, rather than one, addresses tumor heterogeneity: individual tumor cells vary in which antigens they express, and cancers can evade single-target immune pressure by losing that one antigen. A multi-antigen approach broadens the range of tumor cells that can be targeted and reduces the likelihood of complete immune escape. This general strategy — antigen-specific T-cell priming against tumor-restricted proteins — is relevant across solid tumors, including lung cancer, where harnessing adaptive immunity against tumor cells that would otherwise evade detection is a central therapeutic goal.